Autres

Creating Drugs at the Speed of Ai Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug CreationTM platform unlocks the potential to accelerate time to clinic and increase the probability of success by … [voir plus]

Rational design of new molecules and medicines, enabled by the fusion of artificial intelligence and structural biology. Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research … [voir plus]

BigHat Biosciences is a novel protein therapeutics company and developer of an AI-guided antibody design platform BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to … [voir plus]

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs. [voir plus]

Pioneering generative biology to create breakthrough therapeutics. Pioneering generative biology to create breakthrough therapeutics. [voir plus]

Artificial intelligence for new drug design We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization. Our de novo design algorithm is based on deep generative models with reinforcement learning. … [voir plus]

#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning … [voir plus]

Building the future of cell-based therapies. CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive. Cell-based Therapies and Machine Learning [voir plus]

We use AI to find the right treatment for every patient. Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing … [voir plus]

Bridging Vision & Precision Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a … [voir plus]

Histopathology reimagined. PictorLabs, Inc. is a digital pathology company developing an AI-powered virtual staining platform to revolutionize histopathology and accelerate clinical research with the goal of improving patient outcomes. Led by a team with deep expertise in bioengineering, artificial intelligence, and health-tech product development, the Company is reimagining existing histopathology … [voir plus]

Decoding the language of life with AI Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Berkeley, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, … [voir plus]

Industrializing scientific discovery to radically improve lives. Valence Labs, powered by Recursion, is industrializing scientific discovery to radically improve lives. Our vision is that highly autonomous systems capable of Nobel-worthy insights will usher in a new wave of scientific discovery. Following the acquisition of Valence Discovery by Recursion (NASDAQ: RXRX) … [voir plus]